VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant milestone in its oncology pipeline: the VXA-222 bispecific antibody-drug conjugate (bsADC) program has moved beyond the discovery phase into the next stage of development. This follows the successful completion of the discovery phase with OmniAb, which delivered a portfolio of therapeutic antibody binders. VERAXA is now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
While VXA-222 does not utilize VERAXA's proprietary BiTAC platform, it leverages the company's expertise in antibody engineering, linker technologies, and conjugation methods. This program is one of VERAXA's most advanced development efforts, highlighting the company's ability to integrate external collaborations with its internal capabilities.
In conjunction with this development milestone, VERAXA has expanded its intellectual property portfolio. The company recently filed its first patents related to the BiTAC platform, along with additional patents covering conjugation chemistry, payloads, and antibody technologies. This expansion brings VERAXA's total holdings to more than 50 granted, owned, or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, securing the company's innovative technologies for the long term.
The advancement of VXA-222 and the strengthening of its IP portfolio are part of VERAXA's broader strategy to build a diversified oncology pipeline. The company is developing bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats aimed at treating difficult-to-cancers. These efforts position VERAXA as an emerging leader in the design of novel cancer therapies.
The collaboration with OmniAb, which began in May 2025 (https://nnw.fm/nIprz), has been instrumental in advancing VXA-222. With the discovery phase complete, VERAXA will now focus on constructing the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary technologies.
This progress is significant for the biopharmaceutical industry, as it demonstrates the potential of bispecific antibody-drug conjugates to target cancer more precisely while minimizing side effects. By leveraging partnerships and robust IP, VERAXA aims to bring innovative treatments to patients in need.
Investors and industry observers can find the latest news and updates on VERAXA in the company's newsroom at https://nnw.fm/VRXA.
